|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOSR1 |
Gene summary for GOSR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOSR1 | Gene ID | 9527 |
| Gene name | golgi SNAP receptor complex member 1 | |
| Gene Alias | GOLIM2 | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O95249 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9527 | GOSR1 | LZE2T | Human | Esophagus | ESCC | 1.23e-02 | 2.71e-01 | 0.082 |
| 9527 | GOSR1 | LZE4T | Human | Esophagus | ESCC | 5.69e-20 | 4.85e-01 | 0.0811 |
| 9527 | GOSR1 | LZE5T | Human | Esophagus | ESCC | 3.15e-05 | 9.59e-01 | 0.0514 |
| 9527 | GOSR1 | LZE7T | Human | Esophagus | ESCC | 3.32e-09 | 5.54e-01 | 0.0667 |
| 9527 | GOSR1 | LZE8T | Human | Esophagus | ESCC | 1.54e-10 | 2.04e-01 | 0.067 |
| 9527 | GOSR1 | LZE20T | Human | Esophagus | ESCC | 9.42e-04 | 1.69e-01 | 0.0662 |
| 9527 | GOSR1 | LZE22T | Human | Esophagus | ESCC | 5.04e-06 | 3.98e-01 | 0.068 |
| 9527 | GOSR1 | LZE24T | Human | Esophagus | ESCC | 5.89e-23 | 5.42e-01 | 0.0596 |
| 9527 | GOSR1 | LZE21T | Human | Esophagus | ESCC | 3.28e-05 | 2.74e-01 | 0.0655 |
| 9527 | GOSR1 | LZE6T | Human | Esophagus | ESCC | 8.58e-03 | 1.74e-01 | 0.0845 |
| 9527 | GOSR1 | P1T-E | Human | Esophagus | ESCC | 1.58e-03 | 2.90e-01 | 0.0875 |
| 9527 | GOSR1 | P2T-E | Human | Esophagus | ESCC | 2.42e-34 | 5.70e-01 | 0.1177 |
| 9527 | GOSR1 | P4T-E | Human | Esophagus | ESCC | 6.94e-26 | 6.94e-01 | 0.1323 |
| 9527 | GOSR1 | P5T-E | Human | Esophagus | ESCC | 5.30e-19 | 4.06e-01 | 0.1327 |
| 9527 | GOSR1 | P8T-E | Human | Esophagus | ESCC | 2.24e-34 | 5.74e-01 | 0.0889 |
| 9527 | GOSR1 | P9T-E | Human | Esophagus | ESCC | 2.64e-16 | 3.32e-01 | 0.1131 |
| 9527 | GOSR1 | P10T-E | Human | Esophagus | ESCC | 4.83e-18 | 2.97e-01 | 0.116 |
| 9527 | GOSR1 | P11T-E | Human | Esophagus | ESCC | 4.42e-19 | 7.54e-01 | 0.1426 |
| 9527 | GOSR1 | P12T-E | Human | Esophagus | ESCC | 2.47e-37 | 6.65e-01 | 0.1122 |
| 9527 | GOSR1 | P15T-E | Human | Esophagus | ESCC | 5.05e-30 | 5.62e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
| GO:001648210 | Esophagus | ESCC | cytosolic transport | 124/8552 | 168/18723 | 9.69e-14 | 4.69e-12 | 124 |
| GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00069038 | Esophagus | ESCC | vesicle targeting | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
| GO:00482844 | Esophagus | ESCC | organelle fusion | 94/8552 | 141/18723 | 3.72e-07 | 5.16e-06 | 94 |
| GO:00421477 | Esophagus | ESCC | retrograde transport, endosome to Golgi | 63/8552 | 91/18723 | 4.58e-06 | 4.87e-05 | 63 |
| GO:00901743 | Esophagus | ESCC | organelle membrane fusion | 73/8552 | 110/18723 | 9.29e-06 | 8.88e-05 | 73 |
| GO:00069063 | Esophagus | ESCC | vesicle fusion | 70/8552 | 106/18723 | 1.82e-05 | 1.60e-04 | 70 |
| GO:004819914 | Esophagus | ESCC | vesicle targeting, to, from or within Golgi | 19/8552 | 21/18723 | 2.28e-05 | 1.96e-04 | 19 |
| GO:00068914 | Esophagus | ESCC | intra-Golgi vesicle-mediated transport | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:00610254 | Esophagus | ESCC | membrane fusion | 98/8552 | 163/18723 | 1.39e-04 | 9.41e-04 | 98 |
| GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
| GO:000688811 | Liver | Cirrhotic | endoplasmic reticulum to Golgi vesicle-mediated transport | 77/4634 | 130/18723 | 5.78e-17 | 7.56e-15 | 77 |
| GO:001605011 | Liver | Cirrhotic | vesicle organization | 133/4634 | 300/18723 | 7.35e-14 | 6.41e-12 | 133 |
| GO:001648211 | Liver | Cirrhotic | cytosolic transport | 74/4634 | 168/18723 | 3.34e-08 | 1.12e-06 | 74 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041302 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041303 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041304 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| hsa0413011 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOSR1 | SNV | Missense_Mutation | c.190N>T | p.Asp64Tyr | p.D64Y | O95249 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GOSR1 | insertion | Frame_Shift_Ins | novel | c.230_231insAGCTAACGAA | p.Leu78AlafsTer12 | p.L78Afs*12 | O95249 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| GOSR1 | SNV | Missense_Mutation | rs773900657 | c.679N>T | p.Arg227Trp | p.R227W | O95249 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GOSR1 | SNV | Missense_Mutation | novel | c.643N>T | p.Val215Leu | p.V215L | O95249 | protein_coding | tolerated(0.38) | benign(0.019) | TCGA-ZJ-AAXI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| GOSR1 | SNV | Missense_Mutation | c.512N>A | p.Arg171Gln | p.R171Q | O95249 | protein_coding | tolerated(0.06) | probably_damaging(0.957) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| GOSR1 | SNV | Missense_Mutation | c.512N>A | p.Arg171Gln | p.R171Q | O95249 | protein_coding | tolerated(0.06) | probably_damaging(0.957) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GOSR1 | SNV | Missense_Mutation | novel | c.250N>A | p.Val84Ile | p.V84I | O95249 | protein_coding | tolerated(0.46) | benign(0.012) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| GOSR1 | SNV | Missense_Mutation | novel | c.433N>T | p.Asp145Tyr | p.D145Y | O95249 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GOSR1 | SNV | Missense_Mutation | novel | c.608N>T | p.Ser203Ile | p.S203I | O95249 | protein_coding | deleterious(0.01) | possibly_damaging(0.515) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GOSR1 | SNV | Missense_Mutation | c.77N>G | p.Lys26Arg | p.K26R | O95249 | protein_coding | deleterious(0.01) | possibly_damaging(0.831) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |